Capricor Therapeutics (CAPR) Misses Q3 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.29), $0.02 worse than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14